The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.
Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.
Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.